Mergers and Acquisitions in the Pharma-Biotech Industry

Mergers and Acquisitions in the Pharma-Biotech Industry published by Frost & Sullivan in May, 2009. This report price starts from US $ 6000.

Introduction

Abstract

This research service provides insights into M&A activities, trends and strategic analysis in the pharma- biotech space.

Table of Contents

• 1. Introduction
• 2. Top Pharma-Biotech M&As of the Decade, 2008 and 2009
  • 2.1 Top Pharma-Biotech M&As of the Decade
  • 2.2 Top Pharma-Biotech M&As in 2008 and 2009
• 3. Factors Contributing to Consolidation and Impact of Economic Downturn
  • 3.1 Consolidation in the Pharma - Biotech Space
  • 3.2 R&D Expenditure for Launch of a New Molecular Entity
  • 3.3 Revenue Loss due to Patent Expiry
  • 3.4 Impact of Economic Downturn
• 4. Major Biotech Segments and Pipeline by Therapeutic Classes
  • 4.1 Biotech Companies - Major Segments
  • 4.2 Biotech Drugs Pipeline by Therapeutic Classes
• 5. Locations of Biotech Target and Acquiring Companies
  • 5.1 Locations of Biotech Target Companies
  • 5.2 Locations of Biotech Acquiring Companies
• 6. Key Drivers
  • 6.1 Key Drivers for M&A Activity in Pharma-Biotech Industry
  • 6.2 Top Selling Biotech Drugs
  • 6.3 Cash Position of Big Pharma
  • 6.4 Patent Expiry Forecasts of Top Selling Biotech Drugs
• 7. Funding Sources for Biotech Companies
  • 7.2 Decreasing Number of Biotech IPO' s due to Economic Downturn
  • 7.1 Biotech Funding Sources
• 8. Key Restraints for M&A Activity in Pharma-Biotech Industry
• 9. Significant Merger and Acquisitions in 2009
• 10. Conclusion
  • 10.1 Synergies between Big Pharma and Biotech Companies
  • 10.2 Conclusion: M&A Outlook in Pharma-Biotech Industry
• 11. Decision Support Database

Related Reports